Johnson & Johnson

JNJ

Equity

ISIN null / Valor 943981

New York Stock Exchange, Inc (2025-11-17)

USD 199.58+1.86%

Johnson & Johnson
UMushroom community rating:

4.33 28 votes No rating yet

NegativeNeutralPositive

About company

Johnson & Johnson is a diversified healthcare giant engaged in the research, development, and sale of pharmaceuticals, medical devices, and consumer health products. The company operates globally, with a significant focus on innovative medicine across multiple therapeutic areas including Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. Johnson & Johnson is known for its commitment to addressing complex diseases and advancing the field of precision medicine, aiming to develop treatments that are personalized to individual genetic profiles. Through rigorous science and collaboration with healthcare professionals, the company strives to improve patient outcomes and lead in the discovery of groundbreaking medicines and technologies. Johnson & Johnson's approach combines cutting-edge research with a deep understanding of patient needs, aiming to not only treat diseases but also enhance the quality of life for people around the world.

Summarized from source with an LLMView SourceSector: Healthcare

Sales Growth

In Q3 2025, Johnson & Johnson achieved a reported sales increase of 6.8% to $24.0 billion. This growth was driven by an operational sales rise of 5.4% and an adjusted operational sales growth of 4.4%.

Earnings Performance

The company reported earnings per share (EPS) of $2.12 and an adjusted EPS of $2.80 for the third quarter of 2025, reflecting a substantial increase compared to the previous year.

Innovation and Product Approvals

Johnson & Johnson made significant advancements in its pipeline, including approvals for INLEXZO in high-risk non-muscle invasive bladder cancer and TREMFYA subcutaneous in ulcerative colitis. Additionally, the company submitted icotrokinra for plaque psoriasis and reported landmark data for RYBREVANT plus LAZCLUZE in non-small cell lung cancer.

Full-Year Guidance

The company raised its full-year estimated reported sales guidance to $93.7 billion, up 5.7% at the midpoint. Johnson & Johnson also reaffirmed its full-year adjusted EPS guidance of $10.85 at the midpoint, despite absorbing higher tax costs.

Summarized from source with an LLMView Source

Key figures

29.6%1Y

14.1%3Y

33.6%5Y

Performance

19.5%1Y

17.1%3Y

16.8%5Y

Volatility